Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 July 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Optimum bowel cleansing before colonoscopy

This month's issue of the American Journal of Gastroenterology examines a dual-action, low-volume bowel cleanser administered the day before colonoscopy.

News image

Optimal bowel preparation is vital for the efficacy and safety of colonoscopy.

The inconvenience, discomfort, required consumption of large volumes of product, and potential adverse effects associated with some bowel preparations deter patients from colonoscopy, and may provide inadequate cleansing.

A dual-action, non-phosphate, natural orange-flavored, low-volume preparation containing sodium picosulfate and magnesium citrate (P/MC) is being reviewed for bowel cleansing.

Dr Philip Katz and colleagues from Pennsylvania, USA reported that this was a phase 3, randomized, multicenter, assessor-blinded, prespecified non-inferiority, head-to-head study.

The team investigated the efficacy, safety, and tolerability of day-before administration of picosulfate and magnesium citrate vs 2L polyethylene glycol solution, and 2 5-mg bisacodyl tablets in adult patients preparing for colonoscopy.

The primary objective was to demonstrate the non-inferiority of picosulfate and magnesium citrate to 2L PEG-3350 and bisacodyl tablets in overall colon cleansing using a modified Aronchick scale.

The doctors also evaluated the efficacy in the ascending, mid, and recto-sigmoid segments of colon using a modified Ottawa scale.

Patient acceptability and tolerability of the bowel preparations were assessed via a standard questionnaire.

Adverse events related to the bowel preparation were reported by 1% of patients
American Journal of Gastroenterology

The research team assessed safety based on the monitoring of adverse events and meaningful findings on clinical evaluations including physical examinations, vital sign measurements, and electrocardiograms.

A total of 603 patients were randomized to receive either picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets.

The team of doctors noted that based on the Aronchick scale, successful overall cleansing was similar in patients receiving picosulfate and magnesium citrate.

Patients receiving 2L PEG-3350 and bisacodyl tablets picosulfate and magnesium citrate demonstrated non-inferiority to 2L PEG-3350 and bisacodyl tablets in overall cleansing of the colon, as measured by the Aronchick scale.

Similarly, the efficacy of picosulfate and magnesium citrate , as measured by the Ottawa scale, was non-inferior to 2L PEG-3350 and bisacodyl tablets in cleansing the ascending, mid, and recto-sigmoid segments of the colon.

The researchers noted that patient-reported acceptability and tolerability for each item examined on the questionnaire was significantly greater for picosulfate and magnesium citrate compared with 2L PEG-3350 and bisacodyl tablets.

Treatment-emergent adverse events related to the bowel preparation reported by 1% of patients receiving picosulfate and magnesium citrate or 2L PEG-3350 and bisacodyl tablets were nausea, vomiting, and headache.

No clinically meaningful changes were noted in either treatment arm in data collected from physical examinations, vital sign measurements, and ECGs.

Dr Katz's team commented "When administered as a day-before dose, the bowel cleansing effects of picosulfate and magnesium citrate were non-inferior compared with 2L PEG-3350 and bisacodyl tablets using the clinician-rated Aronchick and Ottawa scales."

"Treatment acceptability was significantly more favorable in patients receiving picosulfate and magnesium citrate  than in patients receiving 2L PEG-3350 and bisacodyl tablets."

Am J Gastroenterol 2013; 108: 401409
20 March 2013

Go to top of page Email this page Email this page to a colleague

 22 July 2016 
Upper GI lesions at primary diagnosis in IBD
 22 July 2016 
Fecal calprotectin and IBD
 22 July 2016 
Duodenal villous atrophy and celiac disease
 21 July 2016 
Radiofrequency ablation in Barrett's
 21 July 2016 
HCV eradication and inflammation in cirrhotic patients
 21 July 2016 
Surveillance of Barrett's
 20 July 2016 
Nonselective β-blockers and survival in cirrhosis
 20 July 2016 
Adolescent body mass index and and colorectal cancer risk
 20 July 2016 
Genetic biomarkers and IBD treatment response
 19 July 2016 
Prevention of chemotherapy-induced nausea and vomiting
 19 July 2016 
Longterm clinical follow-up of living liver donors
 19 July 2016 
Screening diabetic patients for NAFLD
 18 July 2016 
Rectal neuroendocrine tumors
 18 July 2016 
Liver stiffness measurement in chronic liver disease
 18 July 2016 
Liver cancer prediction scores in Hep B
 15 July 2016 
Patient reported outcomes in celiac disease
 15 July 2016 
Tonsillectomy and IBD risk
 15 July 2016 
Trainee IBD education in the USA
 14 July 2016 
Screening for familial pancreatic cancer
 14 July 2016 
Fecal calprotection for IBD prognosis
 14 July 2016 
Perianal surgery risk in Crohn's
 13 July 2016 
Lung transplant outcomes in Hep C
 13 July 2016 
Psychological comorbidity and postinfectious IBS
 13 July 2016 
Graft selection strategy in living donor liver transplants
 12 July 2016 
Treatment of pediatric acute liver failure
 12 July 2016 
Therapy for iron deficiency anemia in IBD
 12 July 2016 
Surveillance endoscopy in Barrett's esophagus
 11 July 2016 
Transition to adulthood in celiac disease
 11 July 2016 
Factors that influence access to liver transplant
 11 July 2016 
Disturbed sleep and IBS
 08 July 2016 
Mortality and peptic ulcers
 08 July 2016 
Statins and cirrhosis in Hep B
 08 July 2016 
Genetic risk score and body mass index
 07 July 2016 
Predicting food triggers in eosinophilic esophagitis
 07 July 2016 
Extraperitoneal vs transperitoneal colostomy for hernia
 07 July 2016 
Predictors fecal transplant failure in C. diff infection
 06 July 2016 
Therapies for Hep B cure
 06 July 2016 
Hospital volume and liver cancer survival
 06 July 2016 
Adverse events after outpatient colonoscopy
 05 July 2016 
Colorectal surgery and dialysis
 05 July 2016 
Non-invasive scoring systems for fibrosis in NAFLD
 05 July 2016 
Exercise and gastroesophageal reflux
 04 July 2016 
Guidelines on PPI and NSAID prescription
 04 July 2016 
Rectal cancer surgery checklist
 04 July 2016 
Autoimmunity in eosinophilic esophagitis and families
 01 July 2016 
Outcome measures in celiac disease
 01 July 2016 
Growth factor activity and IBD
 01 July 2016 
Aspirin and colorectal cancer
 30 June 2016 
Staging system for familial adenomatous polyposis
 30 June 2016 
Antibiotics in children and obesity
 30 June 2016 
IBS-type symptoms in pediatric IBD
 29 June 2016 
Hep C eradication in people who inject drugs
 29 June 2016 
Anti-tumor necrosis factor in mothers and newborns
 29 June 2016 
Progression to esophageal carcinoma in Barrett's
 28 June 2016 
Gastric cancer screening in the USA
 28 June 2016 
Cancer recurrence after immune-suppressive therapies
 28 June 2016 
Acute severe ulcerative colitis
 27 June 2016 
Tobacco smoking and ulcerative colitis
 27 June 2016 
Epidemiology of NAFLD
 27 June 2016 
The Toronto Consensus for H. pylori treatment

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us